Bristol-Myers Squibb Company (BMY.BA)
-Buenos Aires 224.10 0.00(0.00%) Nov 27
| Prev Close: | 224.10 |
|---|
| Open: | 224.10 |
|---|
| Bid: | 224.10 |
|---|
| Ask: | 224.10 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 224.10 - 224.10 |
|---|
| 52wk Range: | 79.00 - 224.10 |
|---|
| Volume: | 350 |
|---|
| Avg Vol (3m): | 0 |
|---|
| Market Cap: | 368.10B |
|---|
| P/E (ttm): | 253.79 |
|---|
| EPS (ttm): | 0.88 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in ARS.
Headlines
- Final Glance: Pharmaceuticals companiesAP(Thu, May 23)
- Midday Glance: Pharmaceuticals companiesAP(Thu, May 23)
- Early Glance: Pharmaceuticals companiesAP(Thu, May 23)
- Sanofi says FDA starts review of diabetes drugAP(Tue, Feb 19)
- Qiagen and Lilly expand diagnostic partnershipAP(Wed, Feb 13)
- Bristol-Myers enters three-year collaboration dealAP(Tue, Feb 12)
- Idenix drops development of 2 hepatitis C drugsAP(Mon, Feb 4)
- FDA clears anticlotting drug EliquisAP(Fri, Dec 28)
- Bristol-Myers, Pfizer's Eliquis approved in JapanAP(Wed, Dec 26)
- Medicines Co. strikes 2 deals worth $300MAP(Wed, Dec 12)
- Vical licenses vaccine technology to CyvaxAP(Wed, Dec 5)
- Bristol-Myers Squibb raises dividend to 35 centsAP(Tue, Dec 4)
- Bristol-Pfizer anticlot drug gets key EU approvalAP(Tue, Nov 20)
- EU OKs Bristol-Myers, AstraZeneca diabetes drugAP(Wed, Nov 14)
- FDA has safety concerns over BioCryst's hep C drugAP(Wed, Oct 31)
Reports
- No Reports available for BMY.BA at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 22.72 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide.
View More 
0.08%